US Executive Compensation Proxy SEC Filings — November 10, 2026

Executive Compensation Insights

By Gunpowder Editorial ·

12 high priority 12 total filings analysed

Executive Summary

The 12 DEF 14A filings cluster around a dense late-November/December 2026 annual meeting calendar, with equity plan expansions and dilution management emerging as the dominant governance theme. Six companies (Creative Medical, China Pharma, Veea, Nukkleus/T3 Defense, Nano Dimension, Celularity) are seeking share reserve increases or new incentive plans, several with evergreen provisions that create recurring dilution of 3-5% annually.

Executive compensation disclosures are largely flat or opaque: China Pharma's CEO pay held at $316,000 for the second straight year, while Ainos and Celularity provide pay-versus-performance tables without headline figures. The most material transaction in the set is Saba Capital's BRW fund merger, which carries a mixed risk/reward profile: scale and 8 bps lower other expenses versus a rising fee rate on net assets and a $325,000 sunk reorganization cost. Governance structure changes are notable at Nano Dimension, which lost foreign private issuer status effective January 1, 2026 and is now subject to full SEC proxy rules, and at Nukkleus/T3 Defense, where a 1-for-2 to 1-for-250 reverse split authority plus quarterly CEO share issuances signal Nasdaq listing-compliance pressure and dilution risk. Across the set, there is no revenue or margin data to compare, so the actionable intelligence is concentrated in dilution, compensation alignment, meeting outcomes, and deal approval catalysts.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: DEF 14A

Tracking the trend? Catch up on the prior US Executive Compensation Proxy SEC Filings digest from November 03, 2026.

Investment Signals (10)

  • Merger with Saba Fund II expected to close Q1 2027, offering greater scale/AUM, portfolio diversification, no direct brokerage costs, and 'other expenses' more than 8 bps lower; however, the flat management fee rate means the fee as a percentage of net assets is expected to rise as Managed Assets grow

  • ▲

    First-ever Schedule 14A after ceasing foreign private issuer status on January 1, 2026; seven proposals include removal of KPMG and appointment of PwC Israel (Kesselman & Kesselman), a revised Compensation Policy, and approval of CEO Moshe Rozenbaum's compensation terms — a governance reset that could improve transparency and index eligibility

  • CEO/Chairman Zhilin Li holds 29.42% of shares outstanding (12,657,762 shares, including 12,355,000 voting rights via powers of attorney), and total compensation was flat at $316,000 in both 2025 and 2024 — high insider alignment with no pay escalation [NEUTRAL/BULLISH]

  • Veea Inc. ↓ (NEUTRAL)
    ▲

    Proposed 2024 Equity Incentive Plan amendment raises reserved shares from 553,022 to 750,000 (+196,978) plus an annual evergreen increase of up to 3% of outstanding shares through January 1, 2034 — meaningful but capped dilution

  • 2021 Equity Plan Evergreen Provision would automatically increase reserved shares by up to 5% annually from January 1, 2027 through January 1, 2031 — the highest evergreen rate in the set and a persistent dilution overhang

  • Board seeks discretionary authority for one or more reverse stock splits at ratios from 1-for-2 to 1-for-250 within two years, plus approval of quarterly CEO share issuances under Nasdaq Rule 5635(c) — signals listing-compliance pressure and ongoing dilution

  • ▲

    Six proposals including an equity plan amendment and a financing-related share issuance, with 32,450,679 Class A shares outstanding as of the November 9, 2026 record date and no undesignated preferred outstanding — financing-linked dilution vote is the key swing factor

  • ▲

    Four director nominees and auditor ratification on a fully virtual December 2, 2026 meeting; 62,505,011 shares outstanding as of the October 12, 2026 record date — routine governance with no compensation controversy disclosed

  • Routine four-director election and PwC ratification for FY2026; virtual meeting December 18, 2026 with record date November 10, 2026 — no financial or compensation metrics disclosed

  • ▲

    Pay-versus-performance disclosure covers fiscal years 2021-2025 for CEO Chun-Hsien Tsai, but the filing text contains no specific dollar amounts — compensation alignment cannot be assessed from this filing alone

Risk Flags (8)

  • Evergreen provision of up to 5% annual share reserve increases from 2027-2031 is the most aggressive dilution mechanism in the set; without corresponding performance conditions disclosed, long-term shareholders face cumulative dilution

  • Reverse split authority up to 1-for-250 plus quarterly CEO share issuances under Nasdaq Rule 5635(c) strongly suggests Nasdaq minimum bid price or listing-compliance pressure; Proposals One and Three are non-routine, so abstentions act as votes AGAINST and broker non-votes do not count

  • Saba Capital BRW Merger [MEDIUM RISK]
    ▼

    The $325,000 reorganization cost is borne by BRW whether or not the deal closes, and the management fee as a percentage of net assets is expected to rise due to more Managed Assets even though the fee rate is unchanged — shareholders bear asymmetric cost risk

  • China Pharma Holdings↓ [MEDIUM RISK]
    ▼

    Only 9,800 shares of restricted stock or options were outstanding as of the proxy date, yet the Board seeks a 500,000-share increase to the 2010 Incentive Plan reserve (from 69,600 to 569,600 shares) — a 7x expansion of the reserve relative to current usage raises dilution concerns

  • Celularity Inc↓ [MEDIUM RISK]
    ▼

    A financing-related share issuance is on the ballot alongside an equity plan amendment, indicating capital-raising needs; combined with 32.45 million Class A shares outstanding, dilution could be material

  • Nano Dimension↓ [MEDIUM RISK]
    ▼

    Removal of KPMG LLP and appointment of PwC Israel, plus a revised Compensation Policy and CEO compensation approval in the same meeting, creates execution risk around governance transition in the first year under full SEC proxy rules

  • Veea Inc.↓ [LOW-MEDIUM RISK]
    ▼

    Evergreen provision of up to 3% annually through 2034 compounds with the immediate 196,978-share increase; preferred holders (Series A and Series A-1) also vote, which may dilute common holders' relative influence

  • Ainos, Inc.↓ [LOW RISK]
    ▼

    Pay-versus-performance disclosure without extractable dollar amounts limits shareholders' ability to assess CEO pay alignment; opacity itself is a governance concern

Opportunities (8)

  • Saba Capital BRW (OPPORTUNITY)
    ◆

    If the merger closes in Q1 2027 as expected, scale benefits and more than 8 bps lower 'other expenses' could improve net returns; the December 17, 2026 special meeting is the key catalyst, with proxies due by December 16, 2026

  • Nano Dimension↓ (OPPORTUNITY)
    ◆

    Transition to full SEC proxy rules and a refreshed auditor (PwC Israel) plus a revised Compensation Policy could broaden the investor base and improve governance ratings; AGM December 29, 2026 is the catalyst

  • CEO/Chairman with 29.42% ownership and flat $316,000 compensation for two consecutive years signals strong insider alignment; the 500,000-share plan increase, while dilutive, could be used to incentivize management if tied to performance

  • Veea Inc.↓ (NEUTRAL-POSITIVE)
    ◆

    The 3% evergreen cap is more conservative than Creative Medical's 5%, and the plan expansion to 750,000 shares is modest relative to peers; approval could support retention without excessive dilution

  • Arrive AI Inc.↓ (NEUTRAL-POSITIVE)
    ◆

    Clean governance slate with four director nominees and auditor ratification on December 2, 2026; absence of controversial compensation or dilution proposals reduces event risk

  • Routine director election and PwC ratification with no compensation controversy; virtual meeting December 18, 2026 offers a low-risk governance event

  • ◆

    Say-on-pay and say-on-pay frequency votes alongside the equity plan amendment give shareholders a direct voice on compensation; the December 29, 2026 voting cutoff is the key date

  • Routine four-director election and WithumSmith&Brown ratification on December 17, 2026; no dilution or compensation controversy disclosed

Sector Themes (6)

  • Equity Plan Expansion Wave (DILUTION THEME)
    ◆

    6 of 12 filings (Creative Medical, China Pharma, Veea, Nukkleus/T3 Defense, Nano Dimension, Celularity) seek share reserve increases or new incentive plans; evergreen provisions range from 3% (Veea) to 5% (Creative Medical) annually, implying persistent dilution across small-cap issuers

  • Compensation Disclosure Opacity (GOVERNANCE THEME)
    ◆

    China Pharma is the only filing with explicit CEO pay ($316,000, flat YoY), while Ainos and Celularity provide pay-versus-performance tables without extractable figures; across the set, quantitative compensation data is sparse, limiting shareholders' ability to assess alignment

  • Virtual Meeting Dominance (STRUCTURAL THEME)
    ◆

    At least 7 of 12 annual/special meetings are fully virtual (RoboStrategy, Arrive AI, Saba BRW, Nano Dimension, Veea, Franklin BSP, Nukkleus/T3 Defense), continuing the post-pandemic norm and reducing physical shareholder engagement

  • Nasdaq Compliance and Reverse Splits [RISK THEME]
    ◆

    Nukkleus/T3 Defense's 1-for-2 to 1-for-250 reverse split authority plus quarterly CEO share issuances under Rule 5635(c) is the clearest listing-compliance signal in the set, a pattern common among micro-cap issuers facing bid-price pressure

  • Fund Merger Economics
    ◆

    Saba BRW's merger illustrates a recurring BDC/closed-end fund pattern: scale benefits and lower other expenses are offset by a rising fee rate on net assets and sunk reorganization costs borne by the acquirer [M&A THEME]

  • Foreign Private Issuer Transitions (REGULATORY THEME)
    ◆

    Nano Dimension's loss of FPI status effective January 1, 2026 and first-ever Schedule 14A filing marks a governance tightening trend as Israeli issuers cross the U.S. shareholder threshold

Watch List (8)

  • Saba Capital BRW
    👁

    Special meeting December 17, 2026 at 11:00 a.m. ET; proxies due December 16, 2026; merger expected to close Q1 2027 — watch for shareholder approval and final expense ratios [DATE: 2026-12-17]

  • Virtual special meeting November 30, 2026; reverse split authority and CEO share issuance proposals are non-routine, so abstentions act as votes against — watch for Nasdaq compliance updates [DATE: 2026-11-30]

  • Virtual AGM December 29, 2026 at 5:00 p.m. Israel time (10:00 a.m. ET); watch for auditor transition to PwC Israel and approval of CEO Rozenbaum's compensation terms [DATE: 2026-12-29]

  • Annual meeting December 28, 2026; watch for Evergreen Provision approval and any subsequent 5% share reserve increase effective January 1, 2027 [DATE: 2026-12-28]

  • Annual meeting with record period December 22, 2026; watch for approval of the 500,000-share 2010 Incentive Plan increase and any change to CEO Li's flat $316,000 compensation [DATE: 2026-12-22]

  • Voting cutoff December 29, 2026 at 11:59 p.m. ET; watch for say-on-pay results and approval of the financing-related share issuance [DATE: 2026-12-29]

  • Virtual annual meeting December 28, 2026 at 10:00 a.m. ET; watch for approval of the 196,978-share increase and 3% evergreen provision [DATE: 2026-12-28]

  • Virtual annual meeting December 2, 2026 at 10:00 a.m. ET; registration deadline December 1, 2026 at 9:30 a.m. ET — routine governance, low event risk [DATE: 2026-12-02]

Filing Analyses (12)
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. DEF 14A neutral materiality 4/10

10-11-2026

Creative Medical Technology Holdings filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders to be held December 28, 2026, with a record date of October 30, 2026. Stockholders will vote on four proposals: election of five director nominees, advisory approval of executive compensation, ratification of Haynie & Company as independent auditor for FY2026, and approval of an amendment to the 2021 Equity Plan implementing an Evergreen Provision that would automatically increase reserved shares by up to 5% annually from January 1, 2027 through January 1, 2031. The Board unanimously recommends FOR all proposals; the filing contains no financial results or period-over-period performance data.

  • · Annual Meeting to be held at 9:00 a.m. Pacific Standard Time on December 28, 2026 at 440 Stevens Avenue, Suite #200, Solana Beach, CA 92075
  • · Record Date for voting is October 30, 2026; proxy materials first mailed on or about November 10, 2026
  • · Annual Report on Form 10-K for fiscal year ended December 31, 2025 was filed with the SEC on March 20, 2026
  • · Evergreen Provision would increase reserved shares on January 1, 2027 and each subsequent January 1 through January 1, 2031
  • · Quorum requires one-third of aggregate voting power of Common Stock issued and outstanding
  • · Proxy card must be received by December 27, 2026; internet/telephone voting closes 11:59 p.m. Eastern Time on December 27, 2026
  • · Brokers lack discretionary voting authority on all proposals except the auditor ratification (Proposal 3), which is routine
  • · Company is a Nevada corporation; Corporate Secretary address is 211 E Osborn Road, Phoenix, AZ 85012
RoboStrategy, Inc. DEF 14A neutral materiality 3/10

10-11-2026

RoboStrategy, Inc. filed a definitive proxy statement (DEF 14A) for its annual meeting on December 9, 2026, a fully virtual meeting via live webcast. Stockholders will vote on electing Nicolas Carter as a Class I director to serve until the 2029 annual meeting; the Board unanimously recommends a FOR vote. The filing contains no financial results or period-over-period performance data, only governance and meeting logistics.

  • · Record date for voting is October 30, 2026; proxy materials first sent on or about November 10, 2026
  • · Annual Meeting is fully virtual at meetnow.global/M6G6QHM, starting 10:30 a.m. Eastern Time on December 9, 2026
  • · Director election requires a plurality of votes cast; 'withhold' votes and broker non-votes have no effect on the result
  • · Quorum is one-third of votes entitled to be cast; broker discretionary voting is allowed on the proposal
  • · Proxy voting by mail, internet (www.proxy-direct.com) or phone (1-800-337-3503) must be completed by 11:59 p.m. ET on December 8, 2026
  • · Nicolas Carter is an Independent Director under the Investment Company Act of 1940 and has served on the Board since 2026
  • · Fund is a Maryland corporation headquartered in San Juan, Puerto Rico, with fiscal year end August 31
  • · Annual report to stockholders covers the year ended August 31, 2026
PRINCETON CAPITAL CORP DEF 14A neutral materiality 3/10

10-11-2026

Princeton Capital Corporation filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting to be held December 17, 2026 in Baltimore, Maryland, with a record date of November 9, 2026. Stockholders will vote on electing four directors, ratifying WithumSmith&Brown, PC as independent auditor for FY2026, and approving adjournment if needed; the Board recommends 'FOR' all proposals. The filing is routine governance with no financial results or period-over-period performance data disclosed.

  • · Annual Meeting scheduled for Thursday, December 17, 2026 at 2:00 p.m. Eastern Time at 250 West Pratt Street, Suite 2000, Baltimore, Maryland 21201
  • · Record date for voting is close of business on November 9, 2026
  • · Proxy materials first being sent to stockholders on or about November 16, 2026
  • · Proposal 1 (director election) requires a plurality of votes cast; broker discretionary voting not allowed
  • · Proposal 2 (auditor ratification) requires a majority of votes cast; broker discretionary voting allowed
  • · Company is a Maryland corporation with SEC file number 814-00710 (business development company)
  • · Formerly named Regal One Corp (name changed 2009); fiscal year end December 31
  • · Annual Report on Form 10-K covers fiscal year ended December 31, 2025
CHINA PHARMA HOLDINGS, INC. DEF 14A neutral materiality 4/10

10-11-2026

China Pharma Holdings filed a definitive proxy statement for its 2026 Annual Meeting (record period December 22, 2026), disclosing 43,022,002 shares outstanding as of November 2, 2026. CEO/Chairman Zhilin Li holds 12,657,762 shares (29.42%), including 12,355,000 voting rights held via powers of attorney, giving all directors and officers 29.47% combined. Li's total compensation was flat at $316,000 in both 2025 and 2024 (salary $300,000 plus $16,000 other), while stockholders are asked to approve a 500,000-share increase to the 2010 Incentive Plan reserve (from 69,600 to 569,600 shares).

  • · Board proposes increasing 2010 Incentive Plan reserve by 500,000 shares, from 69,600 to 569,600 shares (Amendment No.3 approved by Board October 23, 2025)
  • · Only 9,800 shares of restricted stock or options were outstanding as of the proxy date
  • · Zhilin Li's employment agreement with Helpson renewed January 1, 2025, expiring December 31, 2029, at RMB400,000 annual salary
  • · Three independent directors' engagement letters renewed December 31, 2025 for one-year terms
  • · Gene Michael Bennett entitled to 25,000 warrants (5,000/year 2021-2025) but none issued as of proxy date; 65,000 warrants issued 2008-2020, none exercised
  • · Enrome LLP appointed as independent registered public accounting firm for fiscal year ending December 31, 2026; auditors will not attend the Annual Meeting
  • · No outstanding equity awards at fiscal year-end
  • · PRC law requires severance for terminated Chinese-national employees (capped at 3x local average monthly salary)
  • · No other executive officer received compensation exceeding $100,000 in fiscal 2025
  • · Compensation Committee members during fiscal 2025: Gene Michael Bennett, Baowen Dong, Yingwen Zhang; no interlocks disclosed
Ainos, Inc. DEF 14A neutral materiality 3/10

10-11-2026

Ainos, Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting, with the record date set at close of business October 27, 2026 and mailing on or about November 10, 2026. The filing includes the 2025 Annual Report and executive compensation disclosures covering fiscal years 2021-2025, including pay-versus-performance data for CEO Chun-Hsien Tsai and other named executives. The filing text provided contains no specific dollar amounts, so no quantitative compensation figures could be extracted.

  • · Record date for voting eligibility: close of business October 27, 2026
  • · Proxy materials mailed on or about November 10, 2026
  • · Each share of Common Stock carries one vote
  • · Pay-versus-performance tables cover fiscal years 2021 through 2025
  • · Chun-Hsien Tsai compensation data begins April 15, 2021 (partial-year period)
  • · Stephen T. Chen compensation data covers fiscal years 2021-2023
  • · Beneficial owners must obtain a legal proxy from their broker to vote
Arrive AI Inc. DEF 14A neutral materiality 4/10

10-11-2026

Arrive AI Inc. (ARAI) filed a DEF 14A proxy statement for its 2026 Annual Meeting, to be held virtually on December 2, 2026 at 10:00 a.m. ET. Stockholders will vote on electing four directors (Daniel O'Toole, John Gallina, Kevin McAdams, Michael Fitz) and ratifying M&K CPAS, PLLC as independent auditor for FY2026. As of the October 12, 2026 record date, 62,505,011 shares of common stock were outstanding and entitled to vote, with no other voting securities outstanding.

  • · Annual Meeting to be held virtually on December 2, 2026 at 10:00 a.m. ET; registration deadline 9:30 a.m. ET on December 1, 2026
  • · Record date for voting is October 12, 2026
  • · Proxy materials first mailed on or about November 10, 2026
  • · Annual Report on Form 10-K for fiscal year ended December 31, 2025 was filed with the SEC on April 15, 2026
  • · Company is a Nevada corporation headquartered at 9100 Fall View Drive, Fishers, IN 46037
  • · AP3 units began revenue operation in 2025
  • · Company has secured pilot programs with a regional hospital and a specialty pharmaceutical delivery company
  • · Three expected primary revenue streams: subscription services, data monetization via ML/AI, and ALM Marketplace
  • · Stockholders are not permitted to cumulate votes in director elections
Saba Capital Income & Opportunities Fund DEF 14A mixed materiality 6/10

10-11-2026

Saba Capital Income & Opportunities Fund (BRW) filed a definitive proxy statement for a special shareholder meeting on December 17, 2026, asking holders to approve issuance of additional common shares to fund the merger of Saba Capital Income & Opportunities Fund II (the Target Fund) into BRW. The Board unanimously recommends voting FOR, citing greater scale/AUM, portfolio diversification, no direct brokerage costs, and expected 'other expenses' more than 8 basis points lower; however, the flat management fee rate stays unchanged, the fee as a percentage of net assets is expected to rise due to more Managed Assets, and the $325,000 reorganization cost is borne by BRW whether or not the deal closes. The merger is contingent on approval by both funds' shareholders and is expected to close in Q1 2027.

  • · Record date for voting: close of business November 2, 2026
  • · Proxy materials first mailed on or about November 11, 2026; proxies due no later than December 16, 2026
  • · Special Meeting at 11:00 A.M. Eastern Time via audio teleconference
  • · Reorganization expected to occur in Q1 2027
  • · No changes to investment objective, strategy, adviser, portfolio management team, fees, fund structure or policies of the Acquiring Fund
  • · BRW is a Massachusetts business trust; Target Fund is a Delaware statutory trust
  • · Reorganization contingent on approval by both Target Fund and Acquiring Fund shareholders plus third-party/lender consents
  • · No expected material federal income tax consequences for Target Fund shareholders or the Combined Fund
  • · Combined Fund intends to continue monthly distributions in the month following closing
  • · BRW would be the accounting and performance survivor of the Reorganization
Celularity Inc DEF 14A neutral materiality 3/10

10-11-2026

Celularity Inc filed a DEF 14A proxy statement for its 2026 Annual Meeting, with 32,450,679 Class A common shares outstanding as of the November 9, 2026 record date and no undesignated preferred stock outstanding. Stockholders will vote on six proposals: election of Class II director Steven N. Gordon, auditor ratification, advisory say-on-pay, say-on-pay frequency, an equity plan amendment, and a financing-related share issuance. The filing is a routine governance document with no financial results or performance metrics disclosed.

  • · Annual Meeting proxy materials first mailed on or about November 10, 2026
  • · Proxy voting cutoff: 11:59 p.m. Eastern Time on December 29, 2026 (telephone/internet); mail ballots due December 29, 2026
  • · Class I directors (Diamandis, Parks, Barach) terms expire at 2028 annual meeting; Class III (Hariri) term expires at 2027 annual meeting
  • · Proposal Nos. 1, 3, 4, 5 and 6 are non-routine, so brokers cannot vote uninstructed shares; only Proposal No. 2 (auditor ratification) is routine
  • · Say-on-pay and say-on-pay frequency votes are advisory and non-binding
  • · Stockholder proposals for next year's proxy due in writing by July 13, 2027; non-inclusion proposals/nominations between September 1, 2027 and October 1, 2027
  • · Directors may be removed only for cause by affirmative vote of at least two-thirds of outstanding shares; board vacancies filled only by majority vote of directors then in office
  • · Final voting results to be published in a Form 8-K within four business days after the Annual Meeting
  • · Company headquarters: 170 Park Ave, Florham Park, New Jersey 07932
Nano Dimension Ltd. DEF 14A neutral materiality 5/10

10-11-2026

Nano Dimension filed its first-ever Schedule 14A proxy statement after ceasing to qualify as a foreign private issuer effective January 1, 2026, now subject to full SEC proxy rules. The 2026 AGM will be held virtually on December 29, 2026 (record date November 4, 2026), with seven proposals including re-election of five directors, removal of KPMG LLP and appointment of Kesselman & Kesselman (PwC Israel) as auditor, say-on-pay votes, extension of the Employee Stock Option Plan, a revised Compensation Policy, and approval of CEO Moshe Rozenbaum's compensation terms. The Board recommends 'FOR' Proposals 1, 2, 3, 5, 6, 7 and 'EVERY ONE YEAR' for Proposal 4; no financial performance figures were disclosed in this filing.

  • · Company ceased to qualify as a foreign private issuer effective January 1, 2026, triggering full Section 14 proxy rules
  • · This is the Company's first filing on Schedule 14A
  • · AGM to be held virtually on December 29, 2026 at 5:00 p.m. Israel time (10:00 a.m. Eastern Time)
  • · Record date for voting: November 4, 2026
  • · Proxy materials first made available on or about November 10, 2026
  • · If quorum (25% of shares) is not present within half an hour, adjourned meeting set for December 29, 2026 at 6:00 p.m. Israel time
  • · Auditor change: removal of KPMG LLP and appointment of Kesselman & Kesselman (PwC Israel) for fiscal year ending December 31, 2025
  • · Auditor's report and consolidated financial statements for year ended December 31, 2025 to be reviewed at the meeting
  • · Company's 2025 Annual Report filed with SEC on March 31, 2026
  • · Company headquarters: 60 Tower Road, Waltham, Massachusetts 02451
VEEA INC. DEF 14A neutral materiality 4/10

10-11-2026

Veea Inc. filed a definitive proxy statement for its 2026 Annual Meeting, to be held virtually on December 28, 2026, with a record date of October 29, 2026. Stockholders will vote on three proposals: electing one Class II director for a three-year term, amending the 2024 Equity Incentive Plan to raise reserved shares from 553,022 to 750,000 (adding 196,978 shares) plus an annual evergreen increase of up to 3% of outstanding shares through January 1, 2034, and ratifying PKF O'Connor Davies, LLP as auditor for fiscal 2026. The Board unanimously recommends 'FOR' all three proposals; the filing contains no financial results or period-over-period performance data.

  • · Annual Meeting to be held virtually at 10:00 AM Eastern Time on Monday, December 28, 2026 via www.virtualshareholdermeeting.com/VEEA2026
  • · Record date for voting is October 29, 2026; holders of common stock, Series A Preferred and Series A-1 Preferred are entitled to vote
  • · Notice of Internet Availability to be sent on or around November 11, 2026; proxy materials available at ProxyVote.com
  • · Stockholders of record will not be able to ask questions prior to or during the Annual Meeting
  • · Company was formerly named Plum Acquisition Corp. I (name change dated January 13, 2021)
  • · Fiscal year ends December 31; 2025 Annual Report on Form 10-K referenced
  • · Stockholder proposals and director nominations for the 2027 Annual Meeting addressed on page 28 of the proxy
Franklin BSP Real Estate Debt, Inc. DEF 14A neutral materiality 3/10

10-11-2026

Franklin BSP Real Estate Debt, Inc. (FBRED) filed a definitive proxy statement (DEF 14A) on November 10, 2026, for its 2026 Annual Meeting to be held virtually on December 18, 2026 at 11:00 a.m. ET. Stockholders will vote on two proposals: electing four director nominees to serve until the 2027 Annual Meeting, and ratifying PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026. The Board unanimously recommends both proposals; no financial performance metrics were disclosed in this filing.

  • · Annual Meeting is virtual-only via live webcast at www.meetnow.global/MGLRLRZ; online access opens at 10:45 a.m. ET
  • · Record date for voting is close of business November 10, 2026
  • · Common stock has $0.001 par value
  • · Proxy materials first sent on or about November 10, 2026, using full set delivery option
  • · Annual Report on Form 10-K for fiscal year ended December 31, 2025 is delivered with the proxy statement
  • · Adviser to the Company is Benefit Street Partners, L.L.C.
  • · Stockholders may vote by Internet at www.proxy-direct.com or by telephone at 1-800-337-3503 until 11:00 a.m. ET on December 18, 2026
  • · A 14-digit control number is required to participate in the virtual meeting
  • · No appraisal rights are available to stockholders in connection with the proposals
  • · Stockholder proposals for the 2027 Annual Meeting are addressed in the filing
Nukkleus Inc. DEF 14A neutral materiality 6/10

10-11-2026

T3 Defense Inc. (filed under Nukkleus Inc. ticker NUKKW) has scheduled a virtual Special Meeting of Stockholders for November 30, 2026, with a record date of November 4, 2026. Stockholders will vote on four proposals: adopting a Second 2026 Equity Incentive Plan authorizing 1,275,000 shares, granting the Board discretionary authority for one or more reverse stock splits at ratios from 1-for-2 to 1-for-250 within two years, approving quarterly CEO share issuances under Nasdaq Rule 5635(c), and approving meeting adjournment if needed. The Board recommends voting FOR all proposals; the reverse split and equity plan proposals signal potential dilution and possible Nasdaq listing-compliance pressure.

  • · Reverse stock split authority would cover ratios from one-for-two up to one-for-two-hundred-fifty, exercisable at Board discretion within two years of the Meeting
  • · Proposal Three seeks approval of quarterly common stock issuances to the CEO to comply with Nasdaq Listing Rule 5635(c)
  • · Proposals One, Three, and Four are classified as non-routine, so broker non-votes will not count and abstentions effectively act as votes AGAINST Proposals One and Three
  • · Proxy materials are first being disseminated on or about November 20, 2026; the meeting is virtual-only via webcast with no physical location
  • · Series B Convertible Preferred Stock carries 10,000 votes per share, giving 152.69 preferred shares outsized voting influence relative to common stock

Get daily alerts with 10 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 12 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US Executive Compensation Proxy SEC Filings

🇺🇸 More from United States

View all →